Your browser doesn't support javascript.
loading
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.
Dimopoulos, M A; Stewart, A K; Masszi, T; Spicka, I; Oriol, A; Hájek, R; Rosiñol, L; Siegel, D; Mihaylov, G G; Goranova-Marinova, V; Rajnics, P; Suvorov, A; Niesvizky, R; Jakubowiak, A; San-Miguel, J; Ludwig, H; Ro, S; Aggarwal, S; Moreau, P; Palumbo, A.
Afiliação
  • Dimopoulos MA; School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Stewart AK; Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ, USA.
  • Masszi T; Department of Hematology and Stem-Cell Transplantation, St. István and St. László Hospital, Semmelweis University, Budapest, Hungary.
  • Spicka I; Department of Internal Medicine, Charles University in Prague, First Faculty of Medicine and General Teaching Hospital, Prague, Czech Republic.
  • Oriol A; Department of Clinical Hematology, Institut Català d'Oncologia-Hospital Universitari Germans Trias i Pujol, Institut Josep Carreras, Barcelona, Spain.
  • Hájek R; Faculty of Medicine, University Hospital Ostrava, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
  • Rosiñol L; Department of Hematology, Hospital Clínic de Barcelona, Barcelona, Spain.
  • Siegel D; Division of Multiple Myeloma, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA.
  • Mihaylov GG; Hematological Clinic, Queen Joanna University Hospital, Sofia, Bulgaria.
  • Goranova-Marinova V; Hematology Clinic, University Multiprofile Hospital for Active Treatment 'Sv. Georgi' and Medical University, Plovdiv, Bulgaria.
  • Rajnics P; Department of Hematology, Mór Kaposi Teaching Hospital, Kaposvár, Hungary.
  • Suvorov A; First Republican Clinical Hospital of Udmurtia, Izhevsk, Russia.
  • Niesvizky R; Multiple Myeloma Center, Weill Cornell Medical College, New York, NY, USA.
  • Jakubowiak A; Myeloma Program, University of Chicago Medicine, Chicago, IL, USA.
  • San-Miguel J; Clinical and Translational Medicine, Clinica Universidad de Navarra-Centro de Investigación Médica Aplicada, IDISNA, CIBERONC, Pamplona, Spain.
  • Ludwig H; Department of Medicine, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria.
  • Ro S; Onyx Pharmaceuticals, Inc., An Amgen Subsidiary, South San Francisco, CA, USA.
  • Aggarwal S; Onyx Pharmaceuticals, Inc., An Amgen Subsidiary, South San Francisco, CA, USA.
  • Moreau P; Department of Hematology, University of Nantes, Nantes, France.
  • Palumbo A; Myeloma Unit, Department of Oncology, University of Turin, Turin, Italy.
Blood Cancer J ; 7(4): e554, 2017 04 21.
Article em En | MEDLINE | ID: mdl-28430175
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oligopeptídeos / Talidomida / Dexametasona / Mieloma Múltiplo Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oligopeptídeos / Talidomida / Dexametasona / Mieloma Múltiplo Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article